Investigation and Analysis of Drug Use in CHD Patients from 8 Medical Institutions in Mianyang Area / 中国药房
China Pharmacy
;
(12): 4487-4492, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-704442
ABSTRACT
OBJECTIVE:
To investigate the situation of drug use in CHD inpatients,and to provide reference for relevant decision-making.METHODS:
Medical records of CHD patients were collected by medical insurance system from 8 medical institutions of Mianyang area during Jan.2014-Dec.2016.Each 200 medical records were collected from each medical institution and then analyzed statistically by EXCEL 2007,ACCESS 2007,SPSS 19.0 software in respects of patient's gender and age,drug amount,drug type,drug combination.RESULTS:
A total of 1 600 patients were included,involving 983 male and 707 female with average age of (73.9 + 10.2) years old.Drug cost ratio was 35.2% of total hospitalization cost;CHD treatment drugs accounted for 72.4% of the total drug cost.Among adjuvant therapy drugs,the cost of Chinese patent medicines and 4 chemical medicines containing TCM extracted component which could improve circulation accounted for 37.8% of cardiovascular drug cost.Among main therapy drugs,the utilization rate of lipid-modulating drugs was 80.8%,and that of ACEI and ARB was 46.9%.The patients receiving antiplatelet drug combined with PPI accounted for 54.9% of the patients receiving antiplatelet drug.Fourteen patients were treated with short-acting Nifedipine tablets.Forty-two patients were treated with clopidogrel and omeprazole.CONCLUSIONS:
The utilization of adjuvant therapy drugs such as L-camitine show high cost ratio.ACEI or ARB,lipid-lowering drugs take up low proportion in CHD patients.The use of short-acting Calcium channel blocker (CCB) and dipyridamole are unreasonable.The indication control of PPIs is lax and the abuse of Chinese patent medicine is obvious.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS